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Summary  
Using geographic information systems and econometric modelling we present the first 
national study evaluating the hospital quality factors that attract patients for radiotherapy 
treatment in health-care markets. We found that one in five men bypassed their nearest 
radiotherapy centre for treatment, especially those who were younger, and more affluent. 
In the absence of indicators reflecting treatment quality, centres that were early adopters of 
intensity modulated radiotherapy or that offered shorter hypofractionated treatment 
schedules were more attractive to patients.   
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Abstract 
Introduction 
Patient choice policies have been introduced across publicly funded health systems to give patients 
more control over their care, and to encourage quality improvement amongst providers. To date we 
have no empirical evidence that patients requiring radiation treatment are prepared to travel to 
alternative more distant centres or the factors that influence this.   
 
Materials and Methods  
We present the results of a national cohort study using administrative hospital data for all 44,363 
men who were diagnosed with prostate cancer and underwent radical radiotherapy in the English 
National Health Service between 2010 and 2014. Using geographic information systems we 
investigated the extent to which men choose to travel beyond (“bypass”) their nearest radiotherapy 
centre and conditional logistic regression to estimate the effect of hospital and patient 
characteristics on this mobility. 
 
Results 
20.7% (n= 9,161) of men bypassed their nearest radiotherapy centre. Travel time had a very strong 
impact on where patients moved to for their treatment, but its effect was smaller for men who were 
younger, more affluent, and from rural areas (p for interaction always <0·001). Men were prepared 
to travel further to hospitals that offered hypofractionated prostate radiotherapy as their standard 
schedule (odds ratio 3.19, p<0.001), to large-scale radiotherapy units (odds ratio 1.56 P<0.001) and 
to hospitals that were early adopters of intensity modulated radiotherapy (odds ratio 1.37, p<0.001). 
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Conclusion 
Men with prostate cancer are prepared to bypass their nearest radiotherapy centres. They are more 
likely to travel to larger established centres and those that offer innovative technology and more 
convenient radiotherapy schedules. Indicators, which accurately reflect the quality of radiotherapy 
delivered are needed to guide patients’ choices for radiotherapy treatment. In their absence, patient 
mobility may negatively affect the efficiency and capacity of a regional or national radiotherapy 
service and offer perverse incentives for technology adoption. 
 
Key Words 
Patient Choice; Hospital Competition; Patient mobility; Technology adoption; Cancer; Equity 
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INTRODUCTION 
Many countries have introduced policies that allow patients to choose the hospital where they have 
their treatment.
1,2
 Patients are expected to choose a hospital that delivers better quality care, and 
the resultant competition between providers as they attempt to attract new patients is expected to 
stimulate improvements in quality. However, for complex treatments such as radiotherapy we have 
no data to support whether patients are prepared to travel to alternative more distant centres, or 
the quality factors which influence this.  
 
It is also debateable whether such policies are relevant in cancer care given the increasing 
centralisation of cancer services which, by its nature, will  reduce the choices available to patients.
3,4
 
Treatment decisions are complex and the therapy itself may last for months resulting in significant 
physical and financial burden for those considering treatment at a more distant hospital. 
Furthermore, there is a lack of valid performance indicators, which accurately reflect the quality of 
cancer treatment, especially radiotherapy. 
 
However, radiotherapy has seen a relentless diffusion of new technologies over the last decade, 
which has shaped clinical practice in both the targeting and delivery of treatment. It has been 
suggested that in certain health care markets, clinicians and hospital providers are encouraged to 
diversify practice through the integration and marketing of new high cost technologies (e.g. proton 
beam therapy) in order to attract new patients. However, this has been largely anecdotal with little 
or no evidence in publicly funded health systems.
5,6
 
 
Using linked patient-level national datasets, geographic information systems, and applied 
econometric modelling, we investigated whether prostate cancer patients, who had radical 
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radiotherapy in the English National Health Service (NHS) “bypassed” their nearest radiotherapy 
provider for treatment, as well as the provider and patient characteristics associated with that 
mobility. 
 
The NHS provides an ideal system for understanding the impact of patient choice policies. It is a 
national single-payer tax-based system where care is free and not based on ability to pay for 
insurance or treatment. The costs of services are fixed under a national tariff and providers are 
therefore expected to compete on quality and not price.
7
 Patients have access to all available NHS 
providers in England with no explicit restrictions on the choices available. 
 
MATERIALS AND METHODS 
We obtained individual patient-level data on all patients diagnosed with prostate cancer between 1
st
 
January 2010 and 31
st
 March 2014 who subsequently underwent radiotherapy in the English NHS. 
Data was retrieved from the National Cancer Registration and Analysis Service (NCRAS) and linked at 
patient level to the National Radiotherapy Dataset (RTDS) and Hospital Episode Statistics (HES) .
8,9
 
Patients who underwent radiotherapy in the private sector were not included in the analysis (<10% 
of eligible patients). 
 
The RTDS provided information on each patient’s radiotherapy treatment: start and finish dates, 
treatment site (primary +/- regional nodes), total dose, number of fractions, and radiotherapy 
technique (Intensity modulated radiotherapy versus 3D conformal radiotherapy). The NCRAS dataset 
provided information on cancer stage and the HES dataset on age and comorbidities. Cancer severity 
was categorised according to a modified D’Amico classification system.
10
 
11,12
 The patients’ place of 
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residence was available as the Lower Layer Super Output Area (LSOA), a geographic area that 
typically includes 1,500 residents or 650 households.
13
 
14
 
 
Travel times 
The population weighted centroids of the patients’ LSOAs (used to define patient residence) and the 
full post-codes for the hospitals where the radiotherapy was undertaken were inputted into a 
geographical information system (ESRI ArcGIS 10.3) to calculate travel times according to the fastest 
route by car (using Ordnance Survey MasterMap Integrated Transport Network). 
 
Assessment of mobility  
All radiotherapy treatment provider (n=57) were ranked according to the distance in terms of drive 
time by car from the patient’s residence. The proportion of patients not receiving care at their 
nearest provider (ranked >1) were considered to be “by-passers”.
15
 
 
We identified for each radiotherapy centre the number of patients for whom that centre was 
nearest but who had their treatment elsewhere - “leavers” – and also those patients for whom 
another radiotherapy centre was nearest but who had their radiotherapy at that centre – “arrivers”. 
A centre was identified as being a “winner” or “loser” of patients if the difference between arrivers 
and leavers was statistically significant.
16
 Patients receiving radiotherapy at their nearest centre 
were defined as “core users”.  
 
Competition indices 
For each centre we also calculated a spatial competition index (SCI) as a measure of “external 
competition”.
17,18
 The SCI provides a uniform metric which can be used across all centres in England 
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to factor in the demand for services and the availability of alternative hospitals for patients to 
choose. In this analysis, the SCI for a radiotherapy centre was calculated based on both the number 
of eligible patients within a 60-minute drive and the number of alternative radiotherapy centres 
within 60-minute drive for each eligible patient: 
SCI = 1 − 1	
1
 	


 
where radiotherapy centre i has n eligible patients within a 60-minute drive and patient j in centre i 
has k alternative radiotherapy centres within a 60-minute drive. The SCI ranges theoretically from 0 
for centres in a monopoly environment to a value close to 1 for centres in the most competitive 
environment. 
 
Patient characteristics  
Four patient level variables were derived from the linked dataset. First, patient age at the time of 
prostate cancer diagnosis. Second, the RCS Charlson Score, was used to identify the number of co-
morbidities.
19
 Third, the Index of Multiple Deprivation (IMD), was used as a measure of the patients’ 
socio-economic deprivation.
20
 The IMD was stratified into quintiles according to the national 
distribution such that 1 represents households in the 20% least deprived and 5 in the 20% most 
deprived LSOAs.  Fourth, the patients’ area of residence was classified as urban or rural.
21
  
 
Hospital characteristics 
At the start of the study, there were 52 radiotherapy centres across England. A further five centres 
opened during the study period. In the absence of publicly reported performance indicators for 
prostate cancer radiotherapy, we created four hospital-level variables as proxies for quality, which 
may make a hospital more attractive to patients when considering where to have radiotherapy 
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treatment. These variables were informed by the peer-reviewed literature, in-depth qualitative 
interviews undertaken by the study team with men previously treated for prostate cancer in the UK, 
and The National Prostate Cancer Audit organisational survey.
22
  
 
We identified the 28 “university teaching hospitals”, based on their membership of the Association 
of UK University Hospitals.
23
 Studies have demonstrated that teaching hospital status is associated 
with higher quality for certain interventions compared to non-teaching hospitals and therefore 
maybe preferentially chosen by patients.
24-28
  
 
Second, we labelled the three hospitals that were delivering intensity-modulated radiotherapy 
(IMRT) as a standard of care at the start of the study period (2010) as “early IMRT adopters”. There 
was emerging evidence at the time that this technique delivered improved outcomes (reduced pelvic 
toxicity) relative to standard 3D conformal techniques. 
29,30
 In addition, IMRT was already a standard 
of care in countries such as the US in 2010 which may have prompted patients to seek treatment at 
centres that offer this technique in the NHS.
29,30
  
 
Third, we identified eight centres which we classified as “large scale radiotherapy units” based on 
the number of Linear accelerators onsite. The median number of Linear accelerators across the 57 
English NHS radiotherapy centres was 4 (range 2-12).
31
 Centres with ≥8 linear accelerators onsite i.e. 
in the top quintile based on the distribution of Linear accelerators were considered to meet this 
criteria. These centres may have been considered preferentially by patients due to their large capital 
and staff infrastructure investment towards radiotherapy facilities or wider reputation effects from 
being regional centres.  
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Fourth, we identified four centres that were delivering hypofractionated radiotherapy (i.e. higher 
dose per treatment delivered over fewer total number of attendances) as their standard dose-
fractionation regimen for prostate cancer at the start of the study period in 2010. Whilst a dose of 
74 Gray delivered over 37 treatments remains the standard of care, hypofractionated regimens 
halve the duration of treatment from eight weeks to four weeks.
32,33
  
 
Statistical analysis  
We used conditional logit regression to model the odds that a patient moved to a particular hospital 
as a function of travel time and hospital and patient characteristics.
34,35
 We created a data set that 
included for each patient a row for each hospital providing prostate cancer radiotherapy at the time 
of treatment (number of hospitals varied between 52 and 57 as five hospitals opened during the 
study period). The dependent variable of the conditional logit model was a dummy variable with a 
value of 1 for the hospital where a patient had his treatment and a value of 0 otherwise. 
 
Travel time was included in the model as the additional time men had to travel beyond their nearest 
hospital to an alternative hospital providing radiotherapy. In this way, we accounted for the 
variation in service configuration across England. Per definition, additional travel time was 0 minutes 
if a patient had his radiotherapy in the nearest radiotherapy centre. 
 
First, we modelled the effect of travel time and individual hospital characteristics on the odds of 
moving to a particular hospital as part of a univariate analysis. In the second model, we included 
both hospital characteristics and travel time as part of a multivariate conditional regression model. 
In the third model, we included travel time, hospital characteristics and the interactions of patient 
characteristics with travel time. Patient characteristics included age, comorbidity, socioeconomic 
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background, and urban or rural residence. We present the results of both models in Tables 3 and 4. 
Stata version 14 was used to undertake the statistical analyses.  
 
RESULTS 
Patient population 
We identified 46,654 men diagnosed with prostate cancer between 1
st
 January 2010 and 31
st
 March 
2014 who subsequently received radiotherapy (Supplementary Material - Appendix 1). Of these 
men, 44,860 received radical radiotherapy. 497 men were excluded as they lived outside England or 
could not be assigned to a NHS radiotherapy provider. The final study cohort comprised 44,363 men 
and patient characteristics are presented in Table 1.  
 
Patient mobility 
9,161 men (20.7%) “bypassed” or travelled beyond their nearest radiotherapy centre to an 
alternative more distant centre (Table 2). 5142 men (12.6%) bypassed only one centre and 1,125 
men (2.5%) bypassed five or more centres for treatment (Table 2). Figure 1 demonstrates the net 
gains and losses of patients by individual prostate cancer radiotherapy centres (n=57) due to patient 
mobility during the study period. 19 out of the 57 centres (33.3%) were classified as “winners” and 
25 out of 57 centres (43.9%) “losers”. 13 centres had no statistically significant net gain or loss of 
patients. Some of the “winners” were treating 500 or more patients than expected if they had been 
operating solely on men for whom they were the nearest centre. Conversely, some of the “losers” 
were treating nearly 400 fewer procedures than expected. When considering the degree of external 
competition faced by each centre, centres experiencing the largest net gains or losses were 
predominantly located in the most competitive areas (SCI between 0.70 and 1) (Figure 2). 
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Impact of travel time and patient and hospital characteristics on patient mobility  
Travel time had a very strong impact on the odds that a patient travelled to a particular hospital to 
receive radiotherapy in the univariate and multivariate conditional regression models (Tables 3 and 
4). The odds of a patient travelling to a hospital that was up to 10 minutes further away than the 
patient’s nearest radiotherapy provider was found to be on average 72% smaller (OR of 0.28) 
according to a conditional logit model that only included additional travel time (Table 3, Model 1). 
The odds of a patient travelling to a particular hospital decreased markedly as the additional travel 
time increased. 
 
The results of the univariate analysis assessing the impact of hospital characteristics on the odds of 
travelling further to a particular hospital are presented in Table 3 (model 1). When considering the 
impact of hospital characteristics on mobility patterns of patients as part of a multivariate regression 
model including travel time and patient characteristics, men were 3.19 times more likely to travel to 
a particular radiotherapy centre if it offered hypofractionated radiotherapy as standard (Table 4, 
Model 3). In addition, patients were 1.56 times more likely to travel to a centre classified as a large-
scale radiotherapy unit, and 1.37 times more likely to travel to a centre if it was an established IMRT 
centre. There was a small but significant increase in the likelihood that patients travelled to a specific 
centre if it had university hospital status (OR 1.19).  
 
The addition of patient characteristics as interaction terms into our model showed that the impact of 
travel time was smaller for men who were younger, and for those who lived in more affluent or rural 
areas because the odds ratios expressing the interaction terms are greater than 1 (Table 4, Model 3). 
The greater the size of the interaction term value the larger its attenuating effect on the impact of 
travel time.  For example, compared to having the radiotherapy at the nearest provider, for men 
classified as living in urban and less affluent areas, who are ≥65, and have comorbidities , the odds of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
travelling to a hospital that was up to 10 minutes further away was estimated to be 82% smaller (OR 
0·18). The corresponding figure for men from rural areas (keeping all other patient characteristics 
the same as described) is 60% smaller (OR 0.40 = 0.18 x 2.23, based on multiplying the odds ratio of 
the main effect of additional travel time with the odds ratio of the interaction term). This implies 
that men from rural areas have a greater odds of travelling to an alternative hospital up to 10 
minutes further away compared to men from urban areas. Different patient characteristics 
attenuate the effect further. For example, men from both rural and affluent areas (positive 
interaction terms) have an even greater odds of travelling to an alternative hospital up to 10 minutes 
further away (keeping all other patient characteristics the same), OR 0.51 (= 0.16 x 2.23 x 1.26), 
compared to men from urban and less affluent areas.   
 
DISCUSSION 
There is limited evidence about what factors inform and influence cancer patients’ choice of 
treatment provider.
1
 In this study, we demonstrate that in the UK NHS, one in five patients who have 
radiotherapy treatment “bypass” their nearest radiotherapy centre. Travel time had a very strong 
impact on where patients received their treatment but this effect was smaller for men who were 
younger, more affluent or living in rural areas. Men were more likely to travel to centres that offered 
shorter hypofractionated radiotherapy regimens as standard for prostate cancer, larger established 
radiotherapy units, and those centres that utilized IMRT earlier. Mobility between providers resulted 
in winners and losers, with some centres treating hundreds more patients each year than expected if 
they only treated local patients. 
 
These findings are relevant across a range of elective secondary care cancer services in countries 
that have introduced patient choice of provider policies.
1
 A substantial number of patients were 
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prepared to bypass their nearest radiotherapy centre despite the absence of comparative provider 
level performance information relating to the quality of radiotherapy treatment and the prolonged 
duration of treatment.  
 
The routine availability of hypofractionated radiotherapy for prostate cancer was the strongest 
hospital-level driver of patient mobility. It is not possible to say whether patients were prepared to 
travel further to these centres because hypofractionated radiotherapy is more convenient or 
because patients considered these centres to be innovative and therefore potentially better.
36
 
However, the potential desire for treatment of shorter duration, correlates with our study findings 
that travel time has a very strong impact on the choices that patients make. In addition, previous 
research has shown that patients are reluctant to undergo radiotherapy compared to other prostate 
cancer treatment modalities due its prolonged duration.
37
 
 
Patients in our cohort were more likely to travel to the three centres labelled as early adopters of 
IMRT despite rapid expansion in the availability of IMRT across centres in England during the study 
period.
38,39
 This suggests that there is a wider reputation effect associated with being an early 
adopter of innovation, and that patients may have considered these centres to be at the forefront of 
technology.
40,41
 To illustrate this point, all three established IMRT centres were also amongst the first 
adopters of stereotactic body irradiation (SBRT) in England.
12
 Similarly, patients were more likely to 
travel to larger scale radiotherapy units, which may have had a wider reputation as being a regional 
centre of excellence for radiotherapy or cancer care more generally.  
                                                                                                                                                                                                                                                          
The patterns of mobility observed has resulted in large and unexpected shifts in market share. 
Radiotherapy centres located in the most competitive areas had significant gains and losses of 
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patients (Figure 2). In the NHS, funding follows the patient,
7
 and therefore centres losing patients 
may have to cease providing that service due to lost income. Such an eventuality has already 
transpired for surgical centres providing radical prostatectomy, several of which have closed in the 
last five years.
42
 This pattern of winners and losers also highlights the inefficiency and wasted 
capacity within the current radiotherapy service, which may further increase as a result of the 
current drive towards opening new radiotherapy centres across England (five opened during the 
study period) to improve access to treatment. Equally the impact on service capacity (e.g.  waiting 
times) needs to be considered for those centres treating significant numbers of out of area patients.  
 
Appropriate implementation of advanced radiation technologies 
In the absence of performance indicators, centres that diversify their clinical practice (for example, 
through the integration of new technology), are potentially more attractive to patients. In the US, 
competition has been a key driver in the rapid expansion of innovative radiation therapies such as 
IMRT, proton beam therapy, and Cyberknife® for the management of prostate cancer to maintain 
market share and attract new patients. This has occurred at significant additional cost without any 
clear evidence for benefits to patients over existing standards of care.
6,30,43-46
  
 
To avoid similar patterns of technology adoption for radiotherapy across different health systems, 
we recommend the use of formal health technology assessment (HTA) processes to support decision 
making regarding the integration of new technologies in publicly funded systems.
5,47
 In contrast to 
new cancer drugs, radiotherapy has remained beyond the remit of HTA.
5
 The Health Economics in 
Radiation Oncology project, which is being carried out under the auspices of the European Society 
for Radiotherapy and Oncology, is attempting to define economic frameworks for assessing the 
clinical and economic benefit of new radiotherapy technologies is still in its infancy.
48
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There is also a necessity to develop valid performance indicators for radiotherapy to guide patient 
decision-making and potentially stimulate improvements in treatment outcomes through “quality 
competition” as patients are responsive to perceived differences in quality.
49
 This is important, given 
the increasing reliance on unsubstantiated web and media based cancer information, especially for 
new technologies.
50,51
 
52
 A series of process indicators have been proposed by professional bodies, 
but these are hard for patients to interpret.
53,54
 Whilst outcome measures are preferable an 
important caveat is that these can only be published following a lag period (for example, toxicity 
measures at one and five years).
55
 
 
Methodological limitations 
Our modelling of patient mobility used centroids of the LSOAs, small geographical regions typically 
made up of approximately 650 households, to represent the location of the patients’ residence. This 
approach has been used in previous studies of patient mobility in England.
56
 However, it is likely that 
the noise added to the travel times will have attenuated rather than enhanced the observed 
relationships. Our model uses average drive times, which is the standardised methodology for these 
analyses and considered superior to straight-line distance. However, we do acknowledge that drive 
times are variable depending on the time of day, which may affect patient’s decision-making. In 
addition, public transport time were not available for this analysis.   
 
We have not included waiting time as a factor influencing provider choice, as these were not publicly 
available for individual centres. Some patients may have considered moving to alternative providers 
to receive quicker treatment, however extensive efforts have been made in the English National 
Health Service to ensure prompt diagnosis and treatment of suspected cancer patients through a 
system of defined targets. 
57,58
 In 2014/2015 95.3% of people treated for urological cancers in the 
NHS began their first definitive treatment within the 31 day target.
59
 Other potential determinants 
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of mobility such as care giver/work location were not available in our dataset, and we were unable 
to assess the effect of disease severity due to incomplete staging data.  However, the overall impact 
on our observed patterns of mobility is likely to be small in the context of up to 20% of patients 
bypassing their nearest provider. The overall predictive probability of our model, despite these 
exclusions is very high, 82% (note models with values above 60% for goodness of fit estimation are 
considered to have a high degree of explanatory power).
60
  
 
CONCLUSIONS 
Men with prostate cancer are prepared to bypass their nearest provider for radical radiotherapy, 
particularly those who are younger and more affluent. They are more likely to travel to larger 
established centres and those that offer innovative technology and shorter radiotherapy schedules. 
Patient mobility varies significantly across regions and between centres and is mainly evident in 
areas where competition between providers is strongest. This in itself implies that competition as a 
mechanism to stimulate improvements in the quality of care can only work in specific parts of the 
country. Indicators, which accurately reflect the quality of radiotherapy delivered, are essential in 
order to guide patients’ choices for radiotherapy treatment. In their absence, patient mobility may 
negatively affect the efficiency and capacity of regional or national radiotherapy services and offer 
perverse incentives for technology adoption even in publicly funded health systems. 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
REFERENCES 
 
1. Aggarwal A, Lewis D, Mason M, Sullivan R, van der Meulen J. Patient Mobility for Elective 
Secondary Health Care Services in Response to Patient Choice Policies: A Systematic Review. 
Med Care Res Rev. 2016. 
2. Siciliani L, Chalkley M, Gravelle H. Policies towards hospital and GP competition in five 
European countries. Health Policy. 2017;121(2):103-110. 
3. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the 
United States. New England Journal of Medicine. 2002;346(15):1128-1137. 
4. Bevan G, Skellern M. Does competition between hospitals improve clinical quality? A review 
of evidence from two eras of competition in the English NHS. BMJ. 2011;343. 
5. Rodin D, Aggarwal A, Lievens Y, Sullivan R. Balancing Equity and Advancement: The Role of 
Health Technology Assessment in Radiotherapy Resource Allocation. Clinical 
Oncology.29(2):93-98. 
6. Nass SJ, Patlak M. Appropriate Use of Advanced Technologies for Radiation Therapy and 
Surgery in Oncology: Workshop Summary. National Academies Press; 2016. 
7. Health Do. A simple guide to payment by results. In: team Pbr, ed. London: Department of 
Health2012. 
8. The National Cancer Registration and Analysis Service TNCRaA. National Cancer Registration 
for England 2016; http://www.ncras.nhs.uk/phe-office-data-release-odr/. 
9. Hospital Episode Statistics 2016. http://content.digital.nhs.uk/hes. 
10. Royal College of Surgeons of England. National Prostate Cancer Audit - Second Year Annual 
Report - Further analysis of existing clinical data and preliminary results from the NPCA 
Prospective Audit. 2015. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
11. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical 
prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically 
localized prostate cancer. Jama. 1998;280(11):969-974. 
12. Royal College of Surgeons of England. National Prostate Cancer Audit - First Year Annual 
Report - Organisation of Services and Analysis of Existing Clinical Data. 2014. 
13. English Indices of Deprivation 2015 - LSOA level 2015. https://data.gov.uk/dataset/english-
indices-of-deprivation-2015-lsoa-level. 
14. Office for National Statistics. 2001 Super Output Areas 2001; 
http://webarchive.nationalarchives.gov.uk/20160105160709/http://www.ons.gov.uk/ons/g
uide-method/geography/beginner-s-guide/census/super-output-areas--soas-/index.html. 
15. Radcliff TA, Brasure M, Moscovice IS, Stensland JT. Understanding rural hospital bypass 
behavior. The Journal of rural health : official journal of the American Rural Health 
Association and the National Rural Health Care Association. 2003;19(3):252-259. 
16. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. Lippincott Williams & Wilkins; 
2008. 
17. Gravelle H, Santos R, Siciliani L, Goudie R. Hospital quality competition under fixed prices. 
2012. 
18. Diller G-P, Kempny A, Piorkowski A, et al. Choice and Competition Between Adult Congenital 
Heart Disease Centers Evidence of Considerable Geographical Disparities and Association 
With Clinical or Academic Results. Circulation: Cardiovascular Quality and Outcomes. 
2014;7(2):285-291. 
19. Armitage JN, van der Meulen JH, Royal College of Surgeons Co-morbidity Consensus G. 
Identifying co-morbidity in surgical patients using administrative data with the Royal College 
of Surgeons Charlson Score. The British journal of surgery. 2010;97(5):772-781. 
20. Data.gov.uk. Index of Multiple Deprivation Score, 2010. In: Government DfCaL, ed2010. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
 
21. Office for National Statistics. The 2011 Rural-Urban Classification For Small Area 
Geographies: A User Guide and Frequently Asked Questions (v1.0). 2013. 
22. Aggarwal A, Nossiter J, Cathcart P, et al. Organisation of Prostate Cancer Services in the 
English National Health Service. Clinical oncology (Royal College of Radiologists (Great 
Britain)). 2016;28(8):482-489. 
23. Association of UK University Hopital members. 2016. 
http://www.aukuh.org.uk/index.php/members/member-organisations. 
24. Varkevisser M, Van Der Geest SA. Why do patients bypass the nearest hospital? An empirical 
analysis for orthopaedic care and neurosurgery in the Netherlands. European Journal of 
Health Economics. 2007;8(3):287-295. 
25. Taylor  DHJ, Whellan  DJ, Sloan  FA. Effects of Admission to a Teaching Hospital on the Cost 
and Quality of Care for Medicare Beneficiaries. New England Journal of Medicine. 
1999;340(4):293-299. 
26. Ayanian JZ, Weissman JS. Teaching Hospitals and Quality of Care: A Review of the Literature. 
Milbank Quarterly. 2002;80(3):569-593. 
27. Keeler EB, Rubenstein LV, Kahn KL, et al. Hospital characteristics and quality of care. Jama. 
1992;268(13):1709-1714. 
28. Allison JJ, Kiefe CI, Weissman NW, et al. Relationship of hospital teaching status with quality 
of care and mortality for Medicare patients with acute MI. Jama. 2000;284(10):1256-1262. 
29. Bauman G, Rumble R, Chen J, Loblaw A, Warde P, Panel IIE. Intensity-modulated 
radiotherapy in the treatment of prostate cancer. Clinical Oncology. 2012;24(7):461-473. 
30. Jacobs BL, Zhang Y, Skolarus TA, Hollenbeck BK. Growth of high-cost intensity-modulated 
radiotherapy for prostate cancer raises concerns about overuse. Health Affairs. 
2012;31(4):750-759. 
31. The National Clinical Analysis and Specialised Applications Team. Radiotherapy Advisory 
Group measures for the UK Radiotherapy Equipment Survey 2013. 2013. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
32. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose 
intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, 
non-inferiority, phase 3 CHHiP trial. The Lancet Oncology. 2016;17(8):1047-1060. 
33. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal 
radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. 
The Lancet Oncology. 2007;8(6):475-487. 
34. McFadden D. Conditional logit analysis of qualitative choice behavior. 1973. 
35. Beukers PD, Kemp RG, Varkevisser M. Patient hospital choice for hip replacement: empirical 
evidence from the Netherlands. The European journal of health economics : HEPAC : health 
economics in prevention and care. 2014;15(9):927-936. 
36. Victoor A, Delnoij DM, Friele RD, Rademakers JJ. Determinants of patient choice of 
healthcare providers: a scoping review. BMC health services research. 2012;12(1):272. 
37. Zeliadt SB, Ramsey SD, Penson DF, et al. Why do men choose one treatment over another?: 
a review of patient decision making for localized prostate cancer. Cancer. 2006;106(9):1865-
1874. 
38. Mayles WP, Cooper T, Mackay R, Staffurth J, Williams M. Progress with Intensity-modulated 
radiotherapy implementation in the UK. Clinical oncology (Royal College of Radiologists 
(Great Britain)). 2012;24(8):543-544. 
39. Aggarwal A, Nossiter J, Cathcart P, Rashbass J, Payne H, van der Meulen J. The National 
Prostate Cancer Audit – Results from the Organisational Survey of NHS Trusts in England. 
Clinical Oncology. 2015;27(3):e3. 
40. Ward PR, Rokkas P, Cenko C, et al. A qualitative study of patient (dis)trust in public and 
private hospitals: the importance of choice and pragmatic acceptance for trust 
considerations in South Australia. BMC Health Serv Res. 2015;15:297. 
41. Victoor A, Delnoij D, Friele R, Rademakers J. Why patients may not exercise their choice 
when referred for hospital care. An exploratory study based on interviews with patients. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
Health expectations : an international journal of public participation in health care and 
health policy. 2016;19(3):667-678. 
42. Aggarwal A, Lewis D, Charman S, Mason M, Sullivan R, Van der Meulen J. Patient mobility for 
radical prostatectomy in the English NHS: its impact on service configuration and technology 
integration. European Journal of Cancer. 2016;72:S187. 
43. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer 
technologies for treating prostate cancer. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 2011;29(12):1517-1524. 
44. Halpern JA, Sedrakyan A, Hsu WC, et al. Use, complications, and costs of stereotactic body 
radiotherapy for localized prostate cancer. Cancer. 2016;122(16):2496-2504. 
45. Sheets NC, Goldin GH, Meyer A, et al. INtensity-modulated radiation therapy, proton 
therapy, or conformal radiation therapy and morbidity and disease control in localized 
prostate cancer. JAMA. 2012;307(15):1611-1620. 
46. Allen AM, Pawlicki T, Dong L, et al. An evidence based review of proton beam therapy: the 
report of ASTRO’s emerging technology committee. Radiotherapy and Oncology. 
2012;103(1):8-11. 
47. van Loon J, Grutters J, Macbeth F. Evaluation of novel radiotherapy technologies: what 
evidence is needed to assess their clinical and cost effectiveness, and how should we get it? 
The Lancet Oncology. 2012;13(4):e169-e177. 
48. Lievens Y, Grau C. Health Economics in Radiation Oncology: Introducing the ESTRO HERO 
project. Radiotherapy and Oncology. 2012;103(1):109-112. 
49. Le Grand J. The other invisible hand: Delivering public services through choice and 
competition. Princeton University Press; 2009. 
50. Basto M, Cooperberg MR, Murphy DG. Proton Therapy Websites: Information Anarchy 
Creates Confusion. BJU international. 2015;115(2):183-185. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
51. Shah A, Paly JJ, Efstathiou JA, Bekelman JE. Physician evaluation of internet health 
information on proton therapy for prostate cancer. International journal of radiation 
oncology, biology, physics. 2013;85(4):e173-177. 
52. Schomas DA, Milano MT, Roeske JC, Mell LK, Mundt AJ. Intensity-modulated radiotherapy 
and the Internet. Cancer. 2004;101(2):412-420. 
53. Danielson B, Brundage M, Pearcey R, et al. Development of indicators of the quality of 
radiotherapy for localized prostate cancer. Radiotherapy and Oncology. 2011;99(1):29-36. 
54. Spencer BA, Steinberg M, Malin J, Adams J, Litwin MS. Quality-of-care indicators for early-
stage prostate cancer. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology. 2003;21(10):1928-1936. 
55. Walker K, Neuburger J, Groene O, Cromwell DA, van der Meulen J. Public reporting of 
surgeon outcomes: low numbers of procedures lead to false complacency. Lancet (London, 
England). 2013;382(9905):1674-1677. 
56. Beckert W, Christensen M, Collyer K. Choice of NHS-funded Hospital Services in England*. 
The Economic Journal. 2012;122(560):400-417. 
57. Department of Health. The Cancer Plan. London: Department of Health 2000. 
58. Department of Health. Cancer Reform Strategy. In. London: Department of Health2007. 
59. NHS England. Cancer Waiting Times, April 2014 to March 2015 - Provider Based. In:2015. 
60. Varkevisser M, van der Geest SA, Schut FT. Do patients choose hospitals with high quality 
ratings? Empirical evidence from the market for angioplasty in the Netherlands. Journal of 
Health Economics. 2012;31(2):371-378. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
22 
 
 
FIGURE CAPTIONS 
Figure 1. Net gain and losses of patients by each radiotherapy centre (blue bars) due to patient 
mobility between 2010-2014 
 
Figure 2. Graph demonstrating the impact of competition (measured by the SCI Index) on the net 
gain or loss of patients for radiotherapy centres between 2010-2014.  
Key: SCI score = 0 Hospital facing weakest competition SCI score =1 Hospital facing strongest 
competition; Size of circle = Number of men expected to have radiotherapy at centre; Blue = Centres 
classified as “Winners”; Green = Centres classified as “Losers”; Orange = Centres with no statistically 
significant gain or loss of patients; Red = Centres offering hypofractionated radiotherapy as 
standard.  
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Table 1. Characteristics of 44,363 men undergoing radical radiotherapy between 2010 and 2014 in 
the English NHS. 
 
 Number % 
Age (years)   
 <65 12,951 29.2 
 65-69 9,453 21.3 
 70-74 12,373 27.9 
 ≥75 9,586 21.6 
      
Cancer severity   
 Advanced 620 1.8 
 Locally advanced 19,037 55.6 
 Intermediate localised 13,292 38.8 
 low risk localised 1,276 3.7 
Insufficient staging information (n=10,138)  
 
      
Number of comorbidities   
 0 34,368 77.5 
 ≥1 9,995 22.5 
    
Index of Multiple Deprivation 
(national quintiles)  
  
 1 (least deprived) 10,832 24.4 
 2 10,780 24.3 
 3 9,651 21.8 
 4 7,336 16.5 
 5 (most deprived) 5,764 13.0 
      
Urban Rural classification*
   
 Urban 33,332 75.1 
 Rural  11,031 24.9 
      
Notes: 
*See text for definition 
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Table 2. Patient mobility of 44,363 men undergoing radical radiotherapy between 2010 and 2014 in 
the English NHS: number of hospitals “bypassed”
 
* and median travel time 
 
 
Number of 
hospitals  
bypassed
 
 
Number of patients (%) 
 
Travel time (mins) 
median (interquartile range) 
 
0 
35202 (79.4) 20.7 (12.1 to 32.7) 
1 5142 (12.6) 
38.3 (23.4 to 53.6) 
2 1764 (4.0) 
44.0 (22.9 to 59.6) 
3 822 (1.9) 
46.7 (34.7 to 60.6) 
4 308 (0.7) 
55.6 (43.3 to 67.3) 
≥ 5 1125 (2.5) 
52.9 (36.8 to 89.8) 
   
Notes: 
*Hospitals are considered to be “bypassed” if a man has radiotherapy in a hospital that is 
further away from his place of residence in terms of travel time by car. 
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Table 3. Impact of travel time and hospital characteristics on patient mobility in 44,363 men 
undergoing radical radiotherapy between 2010 and 2014 in the English NHS. 
 
 
  
Unadjusted 
Odds ratio 
(Model 1) *  
95% CI p value‡ 
Adjusted 
Odds ratio 
(Model 2) † 
95% CI p value‡ 
Impact of additional 
travel time (mins) 
1 <0.001 1 <0.001 
<10 0.28 0.27-0.29 
 
0.27 0.26-0.28 
 
11-30 0.07 0.06-0.07 
 
0.06 0.05-0.06 
 
31-60 0.006 0.005-0.06 
 
0.005 0.004-0.005 
 
>60 0.0002 0.0001-0.0002 
 
0.0002 0.0001-0.0002 
 
    
Impact of hospital 
characteristics     
University hospital 1.28 1.26-1.31 <0.001 1.18 1.14-1.23 <0.001 
Large scale 
radiotherapy unit 
1.95 1.91-1.99 <0.001 1.55 1.48-1.62 <0.001 
Early adopter 
Intensity modulated 
radiotherapy 
1.15 1.11-1.20 <0.001 1.37 1.30-1.46 <0.001 
Hypofractionated 
treatment 
(standard) 
1.73 1.68-1.78 <0.001 3.10 2.92-3.28 <0.001 
 
Notes: 
*Model 1 presents unadjusted odds ratios from the univariate analysis assessing the impact of additional travel 
time and hospital characteristics on the odds that a patient travels to a particular hospital  
†Model 2 presents adjusted odds ratios from the multivariate conditional logit analysis assessing the impact of 
both additional travel time and hospital characteristics on the odds that a patient travels to a particular 
hospital.  
‡ P value based on likelihood ratio test
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Table 4. Impact of travel time and hospital and patient characteristics on patient mobility in 44,363 
men undergoing radical radiotherapy between 2010 and 2014 in the English NHS. 
 
Notes: 
* Model 3 presents adjusted odds ratios from the multivariate conditional logit analysis assessing the impact of 
additional travel time, hospital characteristics and patient characteristics on the odds that a patient travels to a 
particular hospital. 
 
 
Adjusted Odds 
ratio (Model 3)* 
 95% CI p value‡
 
Impact of additional travel time (mins)†   
   1 <0.001 
  <10  0.18 0.16-0.20  
  11-30  0.04 0.04-0.05  
  31-60  0.002 0.002-0.003  
  >60  0.00006 0.00004-0.00009  
 
  
 
 
Impact of hospital characteristics 
 
  
 
    University hospital  1.19 1.14-1.23 <0.001 
    Large scale radiotherapy unit  1.56 1.49-1.63 <0.001 
    Early adopter Intensity modulated radiotherapy  1.37 1.30-1.45 <0.001 
    Hypofractionated treatment (standard)  3.19 3.01-3.37 <0.001 
     
     
 
Difference in impact of additional travel time for selected patient 
characteristics §  
 Younger patients (< 65 years) 
 
Interaction Terms 
 
<0.001 
  <10  1.17 1.07-1.28 
 
  11-30  1.10 1.00-1.21 
  31-60  1.42 1.15-1.76 
  >60  2.01 1.46-2.77 
 Patients without comorbidities  
  
NS 
  <10  0.95 0.87-1.03 
 
  11-30  0.93 0.85-1.02 
  31-60  0.96 0.79-1.17 
  >60  1.24 0.94-1.63 
 Patients from more affluent areas (IMD 1 or 2)  
  
<0.001 
  <10  1.26 1.17-1.36 
 
  11-30  1.20 1.10-1.29 
  31-60  1.08 0.92-1.29 
  >60  1.31 1.05-1.62 
 Patients from rural areas  
  
<0.001 
  <10  2.23 2.04-2.44 
 
  11-30  2.21 2.03-2.42 
  31-60  3.21 2.72-3.79 
  >60  1.87 1.51-2.33 
     
     
     
McFadden’s pseudo R
2
  0.82  
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†Note that the adjusted odds ratios for the impact of additional travel time in model 3 relates to a particular 
patient group: older men (≥ 65 years), with comorbidity (Charlson ≥ 1), from less affluent (IMD 3-5), and urban 
areas 
‡ P value based on likelihood ratio test 
§ The impact of selected patient characteristics on additional travel time is presented as interaction terms. 
These should be multiplied with the corresponding adjusted odds ratio for additional travel time to formulate a 
new odds ratio. Interaction terms can be used in any combination to assess the effect of different patient 
characteristics on the odds that a patient travels to a particular hospital. For example, the adjusted odds ratios 
presented (†) relate to older men (≥ 65 years), with comorbidity (Charlson ≥ 1), from less affluent (IMD 3-5), 
and urban areas. To calculate the new odds ratio for younger and more affluent men travelling 11-30 minutes, 
but who still have comorbidity and live in urban areas, multiply 0.04 (travel time adjusted OR for 11-30 
minutes) by the corresponding interaction term for men who are affluent (1.20) and men living in rural areas 
(2.21). The new odds ratio is 0.04 X 1.20 X 2.21= 0.11. i.e. men with these patient characteristics have a greater 
odds of travelling up to 30 minutes to a particular hospital. 
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Figure 2. 
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